J B Lorens

Summary

Affiliation: Rigel Pharmaceuticals
Country: USA

Publications

  1. ncbi request reprint Optimization of regulated LTR-mediated expression
    J B Lorens
    Rigel, Inc, 240 East Grand Avenue, South San Francisco, California 94080, USA
    Virology 272:7-15. 2000
  2. ncbi request reprint Retroviral delivery of peptide modulators of cellular functions
    J B Lorens
    Rigel, Inc, 240 East Grand Avenue, South San Francisco, California 94080, USA
    Mol Ther 1:438-47. 2000
  3. ncbi request reprint The use of retroviruses as pharmaceutical tools for target discovery and validation in the field of functional genomics
    J B Lorens
    Rigel, Inc, 240 East Grand Avenue, South San Francisco, CA 94080, USA
    Curr Opin Biotechnol 12:613-21. 2001
  4. ncbi request reprint Stable, stoichiometric delivery of diverse protein functions
    J B Lorens
    Rigel, Inc, 240 East Grand Avenue, 1180 Veterans Boulevard, South San Francisco, CA 94080, USA
    J Biochem Biophys Methods 58:101-10. 2004
  5. ncbi request reprint Dominant effector genetics in mammalian cells
    X Xu
    Rigel, Inc, San Francisco, California, USA
    Nat Genet 27:23-9. 2001
  6. ncbi request reprint The Atlantic salmon prepro-gonadotropin releasing hormone gene and mRNA
    H Klungland
    Department of Dairy and Food Industries, Agricultural University of Norway
    Mol Cell Endocrinol 84:167-74. 1992

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Optimization of regulated LTR-mediated expression
    J B Lorens
    Rigel, Inc, 240 East Grand Avenue, South San Francisco, California 94080, USA
    Virology 272:7-15. 2000
    ..This was achieved without using an internal promoter cassette, thus retaining the cis-packaging elements requisite for helper-mediated transfer...
  2. ncbi request reprint Retroviral delivery of peptide modulators of cellular functions
    J B Lorens
    Rigel, Inc, 240 East Grand Avenue, South San Francisco, California 94080, USA
    Mol Ther 1:438-47. 2000
    ..We believe that such approaches might allow for new forms of gene therapy to become available...
  3. ncbi request reprint The use of retroviruses as pharmaceutical tools for target discovery and validation in the field of functional genomics
    J B Lorens
    Rigel, Inc, 240 East Grand Avenue, South San Francisco, CA 94080, USA
    Curr Opin Biotechnol 12:613-21. 2001
    ..Recent innovations in retroviral infection efficiency and expression control have broadened application of the methodology to include libraries of mutagenized cDNAs, peptides and ribozyme genetic effectors...
  4. ncbi request reprint Stable, stoichiometric delivery of diverse protein functions
    J B Lorens
    Rigel, Inc, 240 East Grand Avenue, 1180 Veterans Boulevard, South San Francisco, CA 94080, USA
    J Biochem Biophys Methods 58:101-10. 2004
    ..In particular, the ability to exploit multiple cellular functions will serve to accelerate the functional characterization of gene products and facilitate novel gene therapy approaches...
  5. ncbi request reprint Dominant effector genetics in mammalian cells
    X Xu
    Rigel, Inc, San Francisco, California, USA
    Nat Genet 27:23-9. 2001
    ..Our data indicate that trans-dominant effector peptides can point to potential mechanisms by which signaling systems operate. Such tools may be useful in functional genomic analysis of signaling pathways in mammalian disease processes...
  6. ncbi request reprint The Atlantic salmon prepro-gonadotropin releasing hormone gene and mRNA
    H Klungland
    Department of Dairy and Food Industries, Agricultural University of Norway
    Mol Cell Endocrinol 84:167-74. 1992
    ..Salmon GnRH associated peptide (GAP) differs extensively in sequence and size from the mammalian counterpart. Compared to the GnRH cDNA of a cichlid species the similarity is 69.3% in the protein coding sequence...